1460P IO-Synthesise RCC: Analysis of real-world (RW) health-related quality of life (HRQoL) outcomes with nivolumab for previously treated metastatic renal cell carcinoma (mRCC) using pooled data from France and Germany

MLA

G. Mouillet, et al. “1460P IO-Synthesise RCC: Analysis of Real-World (RW) Health-Related Quality of Life (HRQoL) Outcomes with Nivolumab for Previously Treated Metastatic Renal Cell Carcinoma (MRCC) Using Pooled Data from France and Germany.” Annals of Oncology, vol. 33, Sept. 2022, pp. S1212–13. EBSCOhost, https://doi.org/10.1016/j.annonc.2022.07.1563.

APA

G. Mouillet, J. Bedke, L. Albiges, P. Barthelemy, B. Escudier, V. Gruenwald, P. Ivanyi, H. Mueller-Huesmann, Y-A. Vano, E. von der Heyde, F. Ejzykowicz, F. Brellier, M. Herber, C. Quentric, B.M. Bennett, S. Nere, A. Autengruber, A. Thiery-Vuillemin, & M-O. Grimm. (2022). 1460P IO-Synthesise RCC: Analysis of real-world (RW) health-related quality of life (HRQoL) outcomes with nivolumab for previously treated metastatic renal cell carcinoma (mRCC) using pooled data from France and Germany. Annals of Oncology, 33, S1212–S1213. https://doi.org/10.1016/j.annonc.2022.07.1563

Chicago

G. Mouillet, J. Bedke, L. Albiges, P. Barthelemy, B. Escudier, V. Gruenwald, P. Ivanyi, et al. 2022. “1460P IO-Synthesise RCC: Analysis of Real-World (RW) Health-Related Quality of Life (HRQoL) Outcomes with Nivolumab for Previously Treated Metastatic Renal Cell Carcinoma (MRCC) Using Pooled Data from France and Germany.” Annals of Oncology 33 (September): S1212–13. doi:10.1016/j.annonc.2022.07.1563.